Roquefort Therapeutics Demonstrates Initial Safety In Two An...| MENAFN.COM

Tuesday, 31 January 2023 03:30 GMT

Roquefort Therapeutics Demonstrates Initial Safety In Two Antibody Programmes


(MENAFN- News Direct)

London, UK | January 26, 2023 03:00 AM Eastern Standard Time

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) CEO Ajan Reginald speaks to Proactive's Thomas Warner after announcing that the company's ROQ-A1 and ROQ-A2 Midkine (MDK) antibody programmes have successfully demonstrated safety in pre-clinical studies. Reginald says that he's now hoping to 'move rapidly into efficacy testing'.

Proactive UK Finance News



MENAFN26012023005728012573ID1105479542


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.